Ephedrine

Bronkaid 25mg ephedrine sulfate plus 400mg guaifenesin remains legal as an OTC drug in the US, sold behind the pharmacy counter under the Combat Methamphetamine Epidemic Act with photo ID, federal NPLEx logbook signature, and monthly purchase limits (3.6g per day, 9g per 30-day window per buyer). What was banned by FDA Final Rule was ephedra alkaloids in dietary supplements under DSHEA's unreasonable-risk provision; the agency's first and only such ban. Ma huang capsules sold as supplements are illegal. Pure ephedrine HCl powder from research-chemical suppliers sits in a DEA gray zone; quality and purity vary, and DEA List I scheduling adds legal exposure beyond the consumer protections of pharmaceutical-grade Bronkaid. The behind-counter access friction is real: pharmacist discretion varies by state and individual pharmacy.

On February 11, 2004, HHS Secretary Tommy Thompson and FDA published the final rule banning dietary supplements containing ephedra alkaloids (21 CFR 119.1, 69 Fed. Reg. 6788), declaring an unreasonable risk under the Dietary Supplement Health and Education Act. The decision was triggered by 16,000-plus FDA adverse event reports, the Haller and Benowitz 2000 NEJM review documenting 10 deaths and 13 permanent disabilities among 140 reviewed cases, the RAND/DHHS-commissioned Shekelle 2003 JAMA meta-analysis of 52 trials, the Bent 2003 analysis showing ephedra accounted for 64 percent of all herbal AE reports despite 0.82 percent of herbal sales, and the February 2003 death of Baltimore Orioles pitcher Steve Bechler, attributed in part to ephedra by the medical examiner. A 2005 federal court reversal in Utah was vacated by the 10th Circuit in 2006, restoring the ban.

Baltimore Orioles pitcher Steve Bechler died February 17, 2003 of multi-organ failure following a heat-stroke episode during spring training in Florida. The Broward County medical examiner Dr. Joshua Perper attributed the death in part to ephedra alkaloids in the Cytodyne Xenadrine RFA-1 supplement he was using, citing the mechanism of thermogenic supplementation impairing thermoregulation under exertion in heat. The combination of elevated core temperature, dehydration, ephedra-driven sympathetic activation, and previous-day exertion produced lethal hyperthermia. The Bechler case is the most-cited individual death cited in the FDA 2004 rulemaking. Vikings offensive lineman Korey Stringer died of heat stroke during 2001 training camp; ephedra was co-implicated but the case is less conclusive than Bechler's because Stringer was using a non-ephedra supplement at time of death and had pre-existing risk factors. Cytodyne settled the Bechler family lawsuit in 2008.

Six distinct intrinsic life-threatening pathways are documented, each via a different receptor or circuit mechanism. (1) Fatal arrhythmia from sympathomimetic cardiac stimulation per Haller and Benowitz 2000 NEJM, 47 percent of related cases involved cardiovascular symptoms with hypertension as the most common precipitating finding. (2) Hemorrhagic stroke per the closely-related ephedrine-alkaloid PPA evidence in Kernan NEJM PPA case-control: women using appetite suppressants showed adjusted OR 16.58 (95 percent CI 1.51 to 182.21, p=0.02). (3) Ischemic stroke from catecholamine-induced vasospasm. (4) Fatal MI per Samenuk 2002 Mayo Clin Proc coronary-vasospasm case series. (5) Hypertensive crisis with MAOI co-administration at any dose, dose-independent absolute contraindication. (6) Hyperthermia under exertion per the Bechler heat-stroke mechanism. Plus serotonin syndrome with SSRI/SNRI co-administration per the Boyer NEJM serotonin-syndrome review and Gillman 2005 on the receptor pharmacology.

Yes, with moderate effect size, but the case has weakened. The Shekelle 2003 JAMA meta-analysis of 52 trials found ephedrine alone produced +0.6 kg/month weight loss (95 percent CI 0.2 to 1.0) and ephedrine-plus-caffeine produced +1.0 kg/month (0.7 to 1.3) versus placebo. The Boozer 2002 herbal-ephedra RCT (n=167, 6 months) showed minus 5.3 plus or minus 5.0 kg versus minus 2.6 plus or minus 3.2 kg placebo (p less than 0.001) with lean mass preserved. Lean-mass preservation is the consistent feature that pulled bodybuilders to ephedrine-based ECA stacks pre-ban. The honest comparison: GLP-1s (semaglutide, tirzepatide) deliver 2 to 3 times the effect size with a different and more manageable safety profile for most users. The risk-adjusted case for ephedrine in the modern era is narrow.

Fetal acid-base findings shifted the obstetric-anesthesia consensus. The Lee et al. 2002 Anesth Analg systematic review and the Veeser et al. 2012 meta-analysis both showed phenylephrine produced superior umbilical artery pH compared with ephedrine for spinal-anesthesia hypotension during cesarean delivery. The mechanism: ephedrine's beta-1 agonism crosses the placenta and stimulates fetal metabolism, increasing fetal lactate production and lowering pH; phenylephrine, a pure alpha-1 agonist, restores maternal blood pressure without the fetal-metabolism side effect. The Kinsella et al. 2018 international consensus statement (Anaesthesia) formalized phenylephrine or norepinephrine as first-line, with ephedrine acceptable as second-line only when phenylephrine is contraindicated (e.g., reactive airway, severe maternal asthma, bradycardia).

ECA is the bodybuilding shorthand for Ephedrine + Caffeine + Aspirin, typically dosed at 25mg ephedrine + 200mg caffeine + 81 to 325mg aspirin, two to three times daily, on a 6 to 8 week cycle followed by a 2 to 6 week off-cycle. The protocol predates the 2004 supplement ban; modern users source ephedrine through Bronkaid behind-the-counter purchase. The thermogenic synergy between E and C is real (Astrup 1991 Metabolism crossover and Astrup 1992 Int J Obes 24-week RCT), with caffeine potentiating the ephedrine response by approximately 30 to 40 percent. Aspirin contribution is debated; the original theoretical justification (prostaglandin-mediated thermogenic limitation) has weak empirical support. Side effects compound: insomnia, anxiety, palpitations, hypertension, dry mouth. Tachyphylaxis is the rate-limiting feature; the cycling discipline is a workaround, not a fix. Safety depends entirely on user screening (no MAOI/SSRI/TCA, no CV disease, no exercise in heat) and dose discipline.

Qualitatively yes, quantitatively unsupported in the published evidence base. The Shekelle 2003 JAMA meta-analysis describes a small performance benefit but does not quantify a specific effect size for ephedrine alone, and no independent replicated RCT has quantified one since. The mechanism is plausible (CNS norepinephrine release reduces perceived exertion), and bodybuilders pre-ban broadly reported ECA-stack performance benefit during cutting cycles, but the published effect-size case is weaker than commonly assumed. WADA prohibits ephedrine in-competition; Olympic and professional athletes face sanctions. For non-competitive performance contexts, the risk-adjusted case competes poorly against caffeine alone, creatine, and structured strength-and-conditioning programming.

Ma huang (麻黄, Ephedra sinica) is one of the most-documented herbs in Traditional Chinese Medicine, with continuous textual record from the Shen Nong Ben Cao Jing (神農本草經), the foundational Han-dynasty pharmacopoeia compiled approximately 200 BCE to 200 CE. The classical indication is wind-cold invasion: cold-pattern respiratory presentations with chills, no sweating, body aches, and obstructed lung qi. The most famous formula is Mahuang Tang (麻黃湯, Ephedra Decoction), described in Zhang Zhongjing's Shang Han Lun (傷寒論, Treatise on Cold Damage Disorders) approximately 200 CE: ma huang 9g, gui zhi 6g, xing ren 9g, zhi gan cao 3g. The formula remains in active use in contemporary TCM, with the modern Chinese Pharmacopoeia 2020 classifying ma huang as a restricted-use herb requiring qualified prescriber dispensing. The 1885 isolation of ephedrine by Nagai Nagayoshi at the University of Tokyo bridged the 2,000-year TCM record with Western pharmacology. The Western caution about ma huang preparations parallels the traditional caution: TCM practitioners traditionally prescribed it short-term for acute presentations, never as a daily tonic, which is consistent with the modern safety record.

Classical TCM characterized ma huang as a yang-tonifying, surface-releasing, lung-opening, and water-dispersing herb appropriate only for excess cold-pattern presentations and explicitly contraindicated in deficiency-pattern presentations (sweating, weakness, depleted qi). Maximum classical dosing was 9g per day for short courses (3 to 7 days); never as a daily tonic. Contemporary Chinese Pharmacopoeia 2020 restricts ma huang to qualified prescriber dispensing, with maximum daily dose 5g and explicit warnings on cardiovascular and hyperthyroid contraindications. The traditional caution and the modern Western regulatory caution converge: ma huang is a powerful acute remedy with a narrow safety window, not a daily supplement. This convergence between two independently-developed evidence streams is one of the cleanest cross-lens corroborations in the BioHarmony catalog.